Biology of Blood and Marrow Transplantation
Volume 16, Issue 1, Supplement , Pages S75-S81 , January 2010

Immunotherapy for Pediatric Central Nervous System Tumors

  • Sharon L. Gardner

      Affiliations

    • Division of Pediatric Hematology/Oncology, Steven D. Hassenfeld Children's Center for Cancer and Blood Disorders, New York University, New York, New York
    • Corresponding Author InformationCorrespondence and reprint requests: Dr. Sharon L. Gardner, Steven D. Hassenfeld Children's Center for Cancer and Blood Disorders, 160 E. 32nd Street, 2nd Floor, New York, NY 10016.
    • ,
  • Nabil Ahmed

      Affiliations

    • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas
    • ,
  • Hideho Okada

      Affiliations

    • Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

References 

  1. Gurney JG, Smith MA, Bunin GR. CNS and miscellaneous intracranial and intraspinal neoplasms. In:  Ries LAG,  Smith MA,  Gurney JG, et al. editor. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program, 1975-1995. NIH Publication 99-4649. Bethesda, MD: National Cancer Institute; 1999;
  2. Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood center nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:946–958
  3. Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med. 2005;98:146–152
  4. Miqkou M, Dimopoulos MA, Gavriatopoulou M, et al. Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opin Biol Ther. 2009;9:207–220
  5. Johnson E, Dean S, Sondel PM. Antibody-based immunotherapy in high-risk neuroblastoma. Expert Rev Mol Med. 2007;9:1–21
  6. Belda-Iniesta C, de Castro Carpeno J, Sereno M, et al. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. Clin Transl Oncol. 2008;10:73–77
  7. Bode U, Buchen S, Janssen G, et al. Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J Clin Oncol. 2006;24(Pt 1):1522
  8. Zagzag D, Friedlander DR, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res. 1996;56:182–189
  9. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389–1397
  10. Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using 131I-radiolabelled monoclonal antibodies. J Neurooncol. 1998;38:225–232
  11. Sampson JH, Reardon DA, Friedman AH, et al. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neurooncology. 2005;7:90–96
  12. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362–1368
  13. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186
  14. Ferrara N, Hillan KJ , Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEFG antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400
  15. Vredenburgh JJ, Desjardins A, Herndon JF, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253–1259
  16. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52:791–795
  17. MacKinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leucocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261–1268
  18. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol. 1997;9:139–145
  19. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–1191
  20. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91:3654–3661
  21. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238–241
  22. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy. 2003;5:211–226
  23. Gross G, Gorochov G, Waks T, et al. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989;21:127–130
  24. Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol. 2004;172:7200–7205
  25. Zhang JG, Eguchi J, Kruse CA, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007;13:566–575
  26. Koka V, Potti A, Forseen SE, et al. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol. 2003;26:332–335
  27. Ozaki M, Kishigami S, Yano R. Expression of receptors for neuregulins, ErbB2, ErbB3 and ErbB4, in developing mouse cerebellum. Neurosci Res. 1998;30:351–354
  28. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  29. Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 2000;20:3210–3223
  30. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res. 2003;63:140–148
  31. Schlegel J, Merdes A, Stumm G, et al. Amplification of the epidermal growth factor receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer. 1994;56:72–77
  32. Schlegel J, Stumm G, Brandle K, et al. Amplification and differential expression of members of the erbB gene family in human glioblastoma. J Neurooncol. 1994;22:201–207
  33. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953–962
  34. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240–246
  35. Tavassoli M, Quirke P, Farzaneh F, et al. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer. 1989;60:505–510
  36. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  37. Ahmed N, Ratnayake M, Savoldo B, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67:5957–5964
  38. Gilbertson RJ. ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist. 2005;10:508–517
  39. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. 2005;41:1349–1361
  40. Scheurer ME, Bondy ML, Aldape KD, et al. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 2008;116:79–86
  41. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neurooncology. 2008;10:10–18
  42. Straat K, Liu C, Rahbar A, et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst. 2009;101:488–497
  43. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008;359:539–541
  44. Savoldo B, Rooney CM, Di SA, et al. Epstein-Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110:2620–2630
  45. Rossig C, Bollard CM, Nuchtern JG, et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99:2009–2016
  46. Okada H, Kohanbash G, Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009;29:1–42
  47. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm. 2006;113:477–485
  48. Darnell RB. The importance of defining the paraneoplastic neurologic disorders. [editorial] N Engl J Med. 1999;340:1831–1833
  49. Okada H, Lieberman FS, Edington HD, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene-transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol. 2003;64:13–20
  50. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5:67
  51. Eguchi J, Hatano M, Nishimura F, et al. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 2006;66:5883–5891
  52. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005;7:717–722
  53. Nishimura F, Dusak JE, Eguchi J, et al. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 2006;66:4478–4487
  54. Sasaki K, Zhu X, Vasquez C, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 2007;67:6451–6458
  55. Trumpfheller C, Caskey M, Nchinda G, et al. The microbial mimic poly IC induces durable and protective CD4 + T cell immunity together with a dendritic cell-targeted vaccine. Proc Natl Acad Sci USA. 2008;105:2574–2579
  56. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732–738
  57. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol. 2004;173:3916–3924
  58. Farina C, Krumbholz M, Giese T, et al. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol. 2005;159:12–19
  59. Jack CS, Arbour N, Manusow J, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol. 2005;175:4320–4330
  60. Salazar AM, Levy HB, Ondra S, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery. 1996;38:1096–1103
  61. Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium study (NABTC01-05). J Neurooncol. 2009;91:175–182
  62. Butowski N, Lamborn KR, Lee BL, et al. A North American Brain Tumor Consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009;91:183–189
  63. Zhu X, Nishimura F, Sasaki K, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5:10–25
  64. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Alpha-type 1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934–5937

 Financial disclosure: See Acknowledgments on page S79.

PII: S1083-8791(09)00520-5

doi: 10.1016/j.bbmt.2009.11.003

Biology of Blood and Marrow Transplantation
Volume 16, Issue 1, Supplement , Pages S75-S81 , January 2010

Article Tools

* Image Usage & Resolution